Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06353022
Title Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)
Acronym IFm2022-01
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nantes University Hospital
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
CH de la Côte Basque Bayonne 64109 France Details
CHU Caen Caen 14033 France Details
CHRU DIjon Dijon 21000 France Details
Chd Vendee La Roche-sur-Yon 85925 France Details
CHRU LILLE - Hôpital Claude Huriez Lille 59037 France Details
CHU Limoges Limoges 87000 France Details
CH Lyon Sud Lyon 69495 France Details
IPC Marseille Institut Paoli Calmettes Marseille 13009 France Details
CHU Montpellier Montpellier 34295 France Details
CHU de Nantes Nantes 44093 France Details
APHP Hôpital Saint Louis Paris 75010 France Details
APHP Hôpital Saint-Antoine Paris 75012 France Details
APHP Hôpital La Pitié Salpétrière Paris 75013 France Details
CHU BORDEAUX - Hôpital du Haut Lévêque Pessac 33604 France Details
CHU Poitiers Poitiers 86000 France Details
CHRU Rennes - Hôpital de Pontchaillou Rennes 35033 France Details
ICANS Institut de Cancérologie Strasbourg Europe Strasbourg 67200 France Details
CHU Toulouse Toulouse 31059 France Details
CHU Tours Hôpital Bretonneau Tours 37044 France Details
CHRU Nancy - Hôpitaux de Brabois Vandœuvre-lès-Nancy 54511 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field